INDV Stock Analysis: Buy, Sell, or Hold?
INDV - Indivior PLC Ordinary Shares
$36.87
-0.91 (-2.41%)
▼
5d:
-5.49%
30d:
-8.99%
90d:
-1.58%
HOLD
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 20, 2026 at $38.38 · last confirmed Aug 20, 2026
Strength: 7.2/10
Get Alerted When INDV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INDV shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: INDV shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$71.09
Based on 7.4% avg growth
INTRINSIC VALUE TODAY
$44.14
16.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INDV is currently trading at $36.87, which is considered oversold relative to its 30-day fair value range of $38.15 to $40.52. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.5) compared to its historical average (10.2). Remarkably, the market is currently pricing in an annual earnings decline of 9.5% over the next few years. This pessimistic expectation contrasts with the company's recent 600% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, INDV is in a strong uptrend. The price is currently testing key support at $36.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $49.00 (+32.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INDV is in a strong uptrend. The price is currently testing key support at $36.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $49.00 (+32.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$38.15 -
$40.52
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding INDV? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (49/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.9% below Wall St target ($49.00)
- NEUTRAL: Bottoming setup forming (49/100) — watch for confirmation
- CAUTION: 5-day price weakness (-5.5%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$38.15 -
$40.52
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$36.70
Resistance Level
$40.00
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.55
Wall Street Target
$49.00
(+32.9%)
Revenue Growth (YoY)
13.6%
Earnings Growth (YoY)
600.0%
Profit Margin
26.8%
Valuation Discount vs History
-9.5% cheaper
PE vs Historical
7.6 vs 10.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-9.5%
(market-implied from PE analysis)
1-Year Target
$33.37
(-10%)
2-Year Target
$30.20
(-18%)
3-Year Target
$27.33
(-26%)
3-Yr Target (if PE normalizes)
(PE: 8→10)
$36.92
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 10.8%)
$133.19
(+261%)
Base:
(SPY PE: 7.6, Growth: 10.8%)
$50.11
(+36%)
Bear:
(PE: 6.4, Growth: 10.8%)
$42.59
(+16%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 13.54 | Current EPS (TTM): $2.79
Bull Case
$72.74
(+97%)
Analyst growth 75.0%, PE expands to 14.9
Base Case
$66.13
(+79%)
Market implied 75.0%, PE stable at 13.5
Bear Case
$25.69
(-30%)
Severe decline -20.0%, PE contracts to 11.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.6 to 10.2
Stabilization Target:
$49.81
(+35.1%)
PE Expansion Potential:
+35.1%
Share & Embed Analysis
Last updated: August 23, 2026 5:51 PM ET
Data refreshes hourly during market hours. Next update: 6:51 PM
Data refreshes hourly during market hours. Next update: 6:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INDV showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Barbara Ryan
BUY
31 shares
2026-03-09
Stuart A Kingsley
BUY
940 shares
2026-03-06
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
Advanced INDV Option Strategies
Professional options setups generated by AI based on today's INDV price and gamma walls.
